The MIT engineer’s 3% stake in the company has reaped enormous profits as progress on its COVID-19 vaccine continues.
Pfizer and BioNTech stock is expected to surge following a breakthrough in their Stage 3 vaccine trials.
The biopharmaceutical company will allow the US government to utilise its stocks of remdesivir, following the FDA’s approval to use the drug to treat COVID-19 cases.
This month, CEO Today had the pleasure to connect with Roel Bulthuis - the Managing Director of M Ventures (previously MS Ventures). The company is the strategic venture capital fund of Merck, which Roel established in 2009. M Ventures’…